| Summary: | This guideline covers newer agents for blood glucose control in adults with type 2 diabetes; it does not address care for pregnant women with diabetes. It is a partial update of Type 2 diabetes', NICE clinical guideline 66 (CG 66), published in 2008, which updated NICE clinical guidelines E, F, G and H (2002) and updated and replaced the recommendations on type 2 diabetes in NICE technology appraisal guidance 53 (2002), 60 and 63 (2003). Specifically, this guideline updates and replaces recommendations in sections 1.6, 1.7.1.3, 1.7.2 and 1.7.3 of CG66. The new recommendations from this short guideline use the same levels of HbA1c for the addition of extra glucose-lowering drugs as defined in CG 66 (that is, a value of 6.5% for people on one glucose-lowering drug and 7.5% for people on two or more oral glucose-lowering drugs or people needing insulin). The use of these different levels takes into account the increasing risk of hypoglycaemia with insulin and the clinical and cost-effectiveness of the newer agents. Otherwise, CG 66 stands. This short guideline addresses the licensed indications of drugs as of September 2008. The recommendations do not apply to drugs not yet available in the UK and exclude liraglutide which did not receive UK marketing authorisation for type 2 diabetes during the development of this guideline. Recommendations are consistent with safety information from the European Medicines Agency and the Medicines and Healthcare products Regulatory Agency
|
|---|
| Item Description: | Title from PDF title page. - "Issue date: May 2009.". - "This short clinical guideline partially updates NICE clinical guideline 66. The recommendations have been combined with unchanged recommendations from CG66 in NICE clinical guideline 87.". - "In September 2010 the European Medicines Agency (EMA), the European Union (EU) body responsible for monitoring the safety of medicines, recommended the suspension of the marketing authorisation for rosiglitazone (Avandia, Avandamet and Avaglim) from GlaxoSmithKline. The EMA has concluded that the benefits of rosiglitazone no longer outweigh its risks and the marketing authorisation should be suspended across the EU. The EMA has advised that patients who are currently taking rosiglitazone-containing medicines should make an appointment with their doctor at a convenient time to discuss suitable alternative treatments. Patients are advised not to stop their treatment without speaking to their doctor. NICE does not recommend the use of drugs without marketing authorisation. Therefore, as a result of the EMA's decision, NICE has temporarily withdrawn its recommendations on the use of rosiglitazone in this guideline." |
|---|